Acumen Pharmaceuticals (NASDAQ:ABOS) Coverage Initiated at Deutsche Bank Aktiengesellschaft
Deutsche Bank Aktiengesellschaft initiated coverage on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) in a research report released on Tuesday, MarketBeat Ratings reports. The firm issued a buy rating and a $8.00 price target on the stock. Acumen Pharmaceuticals Trading Up 3.1 % Acumen Pharmaceuticals stock opened at $3.00 on Tuesday. Acumen Pharmaceuticals has […]
More Stories
DHS Defends Immigration Enforcement Following California Marijuana Farm Arrests
By Jacob Burg Administration officials on July 13 defended President Donald Trump’s immigration enforcement operations, including one on a California...
Social Security Checks May Be Smaller This Month, but Some Seniors Have Options
By Jack Phillips Some Social Security recipients could experience a payment garnishment as an agency clawback policy on previous overpayments...
State Trooper, Others Injured in Shooting That Ended at a Kentucky Baptist Church
By T.J. Muscaro A state trooper is wounded and a suspected shooter is dead after an exchange in gunfire on...
Jannik Sinner Beats 2-time Defending Champion Carlos Alcaraz to Win His First Wimbledon Title
By The Associated Press LONDON—Jannik Sinner defeated two-time defending champion Carlos Alcaraz 4–6, 6–4, 6–4, 6–4 on Sunday to win...
Justice Hijacked: Rogue Judges, Dark Money, and the War Against “The Big Beautiful Bill”
By Stephen Zogopoulos, USNN World News I. Introduction: A Nation Overruled When President Trump took office, he pledged to return...
Fidelity National Financial, Inc. (NYSE:FNF) Shares Sold by Envestnet Asset Management Inc.
Envestnet Asset Management Inc. lowered its position in shares of Fidelity National Financial, Inc. (NYSE:FNF – Free Report) by 18.6%...